Many people with chronic lymphocytic leukemia or small lymphocytic lymphoma benefit from ibrutinib treatment up to 8 years: a plain language summary
Abstract
What is this summary about?
This is a plain language summary of a publication describing long-term results from the RESONATE-2 study with up to 8 years of follow-up. The original paper was published in Blood Advances in June 2022.
What were the results?
Researchers looked at 269 adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had not received any treatment for their CLL/SLL. Study participants were randomly divided into two groups: 136 participants received treatment with a drug called ibrutinib, and 133 participants received treatment with a drug called chlorambucil. Participants in the study were treated and followed for up to 8 years, with results showing that more participants who took ibrutinib (59%) were alive without worsening of their disease at 7 years after starting treatment than participants who took chlorambucil (9%). Almost half of the participants (42%) were able to stay on ibrutinib treatment for up to 8 years.
What do the results of the study mean?
In people with CLL or SLL, more participants who were taking ibrutinib were alive without worsening of their disease after 7 years compared with participants who took chlorambucil.
Clinical Trial Registration: NCT01722487 (ClinicalTrials.gov)
Clinical Trial Registration: NCT01724346 (ClinicalTrials.gov)
To read the full Plain Language Summary of this article, click here to view the PDF.
Link to original article here
Acknowledgments
The authors thank the patients who participated in the study and their supportive families, as well as the investigators and clinical research staff from the study centers. Editorial support for development of this summary was provided by Melanie Sweetlove, MSc, of ApotheCom, and was funded by Pharmacyclics LLC, an AbbVie Company.
Financial & competing interests disclosure
PM Barr reports a consultancy/advisory role with AbbVie, AstraZeneca, Bristol Myers Squibb, Celgene, Genentech, Gilead, Janssen, MEI Pharma, Merck, Morphosys, Pharmacyclics LLC, an AbbVie Company, Seattle Genetics, and TG Therapeutics; research funding from AstraZeneca and TG Therapeutics; C Owen reports honoraria from AbbVie, AstraZeneca, BeiGene, Gilead, Incyte, Janssen, Merck, and Roche; T Robak reports honoraria from AstraZeneca, BeiGene, and Janssen; consultancy/advisory role with and research funding from Acerta, AstraZeneca, BeiGene, and Janssen; A Tedeschi reports a consultancy/advisory role and speakers bureau for AbbVie, AstraZeneca, BeiGene, and Janssen; O Bairey reports a consultancy/advisory role with AbbVie, AstraZeneca, and Janssen; research funding from Janssen; JA Burger reports honoraria and travel expenses from Gilead, Janssen, Novartis, TG Therapeutics, and Pharmacyclics LLC, an AbbVie Company; research funding from AstraZeneca, BeiGene, and Pharmacyclics LLC, an AbbVie Company; consulting/advisory role and speakers' bureau for BeiGene, Gilead, Janssen, Pharmacyclics LLC, an AbbVie Company, and TG Therapeutics; P Hillmen reports a consultancy/advisory role with AbbVie, AstraZeneca, and Janssen; research funding from AbbVie, AstraZeneca, Gilead, Janssen, Novartis/GSK, Pharmacyclics LLC, an AbbVie Company, and Roche; speakers' bureau for AbbVie, AstraZeneca, Janssen, and Roche; travel expenses from AbbVie and Janssen; C Dearden, S Grosicki, J Li and F Offner report no relevant disclosures; H McCarthy reports honoraria and travel expenses from Janssen; consultancy/ advisory role with AbbVie and Janssen; C Moreno reports a consultancy/advisory role with AbbVie, AstraZeneca, BeiGene, and Janssen; research funding from and speakers' bureau for AbbVie and Janssen; M Jermain reports employment and stock or other ownership with Pharmacyclics LLC, an AbbVie Company (self) and Gilead Sciences (family member); C Zhou, E Hsu and A Szoke report employment with Pharmacyclics LLC, an AbbVie Company; stock ownership in AbbVie; TJ Kipps reports a consultancy/advisory role with AbbVie, Celgene, Genentech-Roche, Gilead, and Pharmacyclics LLC, an AbbVie Company; research funding from AbbVie, GenentechRoche, Oncternal Therapeutics, and Pharmacyclics LLC, an AbbVie Company; P Ghia reports honoraria from and consultancy/advisory role with AbbVie, AstraZeneca, ArQule/MSD, Celgene/Juno/Bristol Myers Squibb, Janssen, Lilly/Loxo, MEI Pharma, and Roche; research funding from AbbVie, AstraZeneca, Janssen, and Sunesis.
Open access
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/